T1-IR^TM induces a type-1 inflammation inside the tumor destroying layers over layers of tumor tissue by providing the lacking cytokines necessary to activate patients' tumor-infiltrating immune cells to eliminate their tumors. It can also generate immune protection against relapses (self-vaccination against the tumor).  T1-IR^TM has the potential to be effective against a variety of cancer including solid tumors from colon, lung, breast, kidney, lymphoma and skin.